Drugs / OmniLenz®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06539663 | Apr 2022 → Feb 2024 | corneal infection, exposure keratitis, perforated corneal ulcer | Farwaniya Hospital | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OmniLenz | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06539663 ↗ |